Ejvind Mørtz

Ejvind Mørtz

Auto-generated profile, based on publicly available information

Ejvind Mørtz

Alphalyse A/S, Odense, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2014 in Nature Communications
Verified
Journal Article
Open access
AKAnil Koul
Anil Koul
LVLuc Vranckx
Luc Vranckx
Neeraj DharNeeraj Dhar
Neeraj Dhar
HGHinrich W.H. Göhlmann
Hinrich W.H. Göhlmann
EÖEmre Özdemir
Emre Özdemir
DBDirk Bald
Dirk Bald
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multidrug-resistant tuberculosis in decades. Though BDQ has shown excellent efficacy in clinical trials, its early bactericidal activity during the first week of chemotherapy is minimal. Here, using microfluidic devices and time-lapse microscopy of Mycobacterium tuberculosis, we confirm the absence of significant bacteriolytic activity during the first 3-4 days of exposure to BDQ. BDQ-induced inhibition of ATP synthesis leads to bacteriostasis within hours after drug addition. Transcriptional and proteomic analyses reveal that M. tuberculosis responds to BDQ by induction of the dormancy regulon and activation of ATP-generating pathways, thereby maintaining bacterial viability during initial drug exposure. BDQ-induced bacterial killing is significantly enhanced when the mycobacteria are grown on non-fermentable energy sources such as lipids (impeding ATP synthesis via glycolysis). Our results show that BDQ exposure triggers a metabolic remodelling in mycobacteria, thereby enabling transient bacterial survival.

6 August 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EME Mørtz
E Mørtz
POP B O'Connor
P B O'Connor
PRP Roepstorff
P Roepstorff
NKN L Kelleher
N L Kelleher
Troy Dale WoodTroy Dale Wood
Troy Dale Wood
MMM Mann
M Mann
Molecular and fragment ion data of intact 8- to 43-kDa proteins from electrospray Fourier-transform tandem mass spectrometry are matched against the corresponding data in sequence data bases. Extending the sequence tag concept of Mann and Wilm for matching peptides, a partial amino acid sequence in the unknown is first identified from the mass differences of a series of fragment ions, and the mass position of this sequence is defined from molecular weight and the fragment ion masses. For three studied proteins, a single sequence tag retrieved only the correct protein from the data base; a fourth protein required the input of two sequence tags. However, three of the data base proteins differed by having an extra methionine or by missing an acetyl or heme substitution. The positions of these modifications in the protein examined were greatly restricted by the mass differences of its molecular and fragment ions versus those of the data base. To characterize the primary structure of an unknown represented in the data base, this method is fast and specific and does not require prior enzymatic or chemical degradation.

1 January 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NBNiels Behrendt
Niels Behrendt
OJOle N. Jensen
Ole N. Jensen
LELars H. Engelholm
Lars H. Engelholm
EMEjvind Mørtz
Ejvind Mørtz
MMMatthias Mann
Matthias Mann
KDKeld Danø
Keld Danø
The plasminogen activation cascade system, directed by urokinase and the urokinase receptor, plays a key role in extracellular proteolysis during tissue remodeling. To identify molecular interaction partners of these trigger proteins on the cell, we combined covalent protein cross-linking with mass spectrometry based methods for peptide mapping and primary structure analysis of electrophoretically isolated protein conjugates. A specific tri-molecular complex was observed upon addition of pro-urokinase to human U937 cells. This complex included the urokinase receptor, pro-urokinase, and an unknown, high molecular weight urokinase receptor-associated protein. The tryptic peptide mixture derived from a cross-linked complex of pro-urokinase and the latter protein was analyzed by nanoelectrospray tandem mass spectrometric sequencing. This analysis identified the novel protein as the human homologue of a murine membrane-bound lectin with hitherto unknown function. The human cDNA was cloned and sequenced. The protein, designated uPARAP, is a member of the macrophage mannose receptor protein family and contains a putative collagen-binding (fibronectin type II) domain in addition to 8 C-type carbohydrate recognition domains. It proved capable of binding strongly to a single type of collagen, collagen V. This collagen binding reaction at the exact site of plasminogen activation on the cell may lead to adhesive functions as well as a contribution to cellular degradation of collagen matrices.

1 May 1994 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
EMEjvind Mørtz
Ejvind Mørtz
OVOle Vorm
Ole Vorm
MMMatthias Mann
Matthias Mann
PRPeter Roepstorff
Peter Roepstorff

16 June 2011 in Bioanalysis
Verified
Journal Article
Closed access
SLSteve Lowes
Steve Lowes
JJJim Jersey
Jim Jersey
RSRonald Shoup
Ronald Shoup
FGFabio Garofolo
Fabio Garofolo
NSNatasha Savoie
Natasha Savoie
DHDennis Heller
Dennis Heller
"The Global CRO Council (GCC) for Bioanalysis was formed in an effort to bring together many CRO leaders to openly discuss bioanalysis and the regulatory challenges unique to the outsourcing industry"

1 October 2021 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
KPKatrine Pilely
Katrine Pilely
MJMartin Rask Johansen
Martin Rask Johansen
RLRikke Raaen Lund
Rikke Raaen Lund
TKThomas Kofoed
Thomas Kofoed
TJThomas Kjærsgaard Jørgensen
Thomas Kjærsgaard Jørgensen
EMEjvind Mørtz
Ejvind Mørtz
During biologics development, manufacturers must demonstrate clearance of host cell impurities and contaminants to ensure drug purity, manufacturing process consistency, and patient safety. Host cell proteins (HCPs) are a major class of process-related impurities and require monitoring and documentation of their presence through development and manufacturing. Even in residual amounts, they are known to affect product quality and efficacy as well as patient safety. HCP analysis using enzyme-linked immunosorbent assay (HCP-ELISA) is the standard technique, due to its simple handling, short analysis time, and high sensitivity for protein impurities. Liquid chromatography mass spectrometry (LC–MS) is an orthogonal method for HCP analysis and is increasingly included in regulatory documentation. LC–MS offers advantages where HCP-ELISA has drawbacks, e.g., the ability to identify and quantify individual HCPs. This article summarizes the available knowledge about monitoring HCPs in biologics and presents the newest trends in HCP analysis with current state-of-the-art HCP measurement tools. Through case studies, we present examples of HCP control strategies that have been used in regulatory license applications, using an MS-based coverage analysis and HCP-ELISA and LC–MS for HCP quantification. This provides novel insight into the rapid evolving strategy of HCP analysis. Improvements in technologies to evaluate HCP-ELISA suitability and the implementation of orthogonal LC–MS methods for HCP analysis are important to rationally manipulate, engineer, and select suitable cell lines and downstream processing steps to limit problematic HCPs.